Oppenheimer Asset Management Inc. Acquires 14,677 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)

Oppenheimer Asset Management Inc. grew its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 37.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 53,590 shares of the medical equipment provider's stock after purchasing an additional 14,677 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Smith & Nephew SNATS were worth $1,520,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Sei Investments Co. boosted its stake in Smith & Nephew SNATS by 229.8% in the 4th quarter. Sei Investments Co. now owns 75,215 shares of the medical equipment provider's stock worth $1,849,000 after purchasing an additional 52,411 shares in the last quarter. Townsquare Capital LLC raised its holdings in Smith & Nephew SNATS by 19.0% in the fourth quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider's stock worth $432,000 after buying an additional 2,798 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Smith & Nephew SNATS in the fourth quarter worth approximately $435,000. Barclays PLC purchased a new stake in shares of Smith & Nephew SNATS during the fourth quarter valued at approximately $431,000. Finally, Principal Securities Inc. grew its holdings in shares of Smith & Nephew SNATS by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after buying an additional 691 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Performance

SNN stock traded down $0.04 on Tuesday, hitting $30.59. The company had a trading volume of 789,975 shares, compared to its average volume of 816,375. The company has a current ratio of 2.89, a quick ratio of 1.33 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a 12-month low of $23.69 and a 12-month high of $31.72. The stock has a market cap of $13.40 billion, a price-to-earnings ratio of 14.16, a P/E/G ratio of 0.94 and a beta of 0.69. The stock's 50-day simple moving average is $28.86 and its 200 day simple moving average is $27.17.

Analysts Set New Price Targets

SNN has been the subject of a number of recent analyst reports. Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. UBS Group lowered Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. HSBC downgraded Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Canaccord Genuity Group increased their price objective on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research report on Thursday, May 1st. Six analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $28.00.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.